In swine grower-finisher production batches where recurrent Escherichia coli-induced cystitis, hematuria, and secondary renal pelvis inflammation are documented during post-weaning and pre-slaughter phases, water-medication delivery of a standardized Dianthi Herba extract is implemented during the therapeutic window when feed intake typically drops by 15–25% but drinking water consumption remains within 88–102% of baseline, as recorded by electronic nipple-drinker flow sensors on commercial 1,200-head wean-to-finish sites. The API is typically a 10:1 aqueous-ethanolic extract standardized to total dianthin saponin content of 12.0–18.0% w/w, with total flavonoids at 2.0–4.0% w/w and ethanol-soluble extractives exceeding 30% per the Chinese Veterinary Pharmacopoeia (2020 edition) monograph for Qu Mai. Manufacturing of the water-soluble granules begins with spray drying of the liquid extract at inlet temperature 165–180°C and outlet temperature 70–90°C, using a rotary atomizer operating at 15,000–20,000 rpm and feed solids concentration of 25–35% w/w; maltodextrin with dextrose equivalent 10–20 is incorporated as the primary carrier at extract-to-carrier ratios from 1:1 to 1:3 w/w, yielding spherical particles with median diameter D₅₀ between 20 μm and 80 μm as verified by laser diffraction on a Malvern Mastersizer 3000. The spray-dried intermediate exhibits hygroscopicity thresholds that require blending with colloidal silicon dioxide at 0.5–2.0% w/w and anhydrous sodium sulfate at 1.0–3.0% w/w to suppress moisture pickup at 75% RH and 25°C below 3.5% weight gain over 48 hours, measured according to the dynamic vapor sorption methodology described in USP <922>. Final granulation is performed in a fluid bed processor equipped with a top-spray insert; the granulating fluid consists of a 5% w/w aqueous solution of polyvinylpyrrolidone K30 applied at spray rate 80–120 g/min, inlet air temperature 55–65°C, product temperature 38–45°C, and atomizing air pressure 1.5–2.5 bar, with drying continued until loss on drying is below 5.0% per Ph. Eur. 2.2.32. Dissolution performance in drinking water is confirmed by dispersing 1.0 g of the finished granule product in 1 L of deionized water at 25°C with mechanical stirring at 100 rpm; complete dissolution is required within 3 minutes, and the resulting solution must remain free of sediment for at least 24 hours at ambient temperature when protected from light. Compliance for this application pathway is anchored to EU Regulation 2019/6 on veterinary medicinal products for therapeutic claims, while feed-additive positioning falls under EU Regulation 1831/2003; manufacturing quality systems are audited against EU GMP Part II and ISO 22000:2018 for feed safety management. Terminal finished product forms include 100 g, 500 g, and 1 kg aluminum-foil laminated sachets of water-soluble granules, screw-cap HDPE jars of dry soluble powder containing dosing scoops calibrated for 1 g and 5 g increments, and pre-measured effervescent tablets for water tank application.

How Does Dianthi Herba Extract Survive High-Shear Extrusion in Pelletized Broiler Feed?

The primary constraint governing application in pelleted broiler feed is thermal degradation of dianthin triterpenoid saponins during condition-and-pellet processing, where feed mash is subjected to steam conditioning at temperatures that routinely reach 70–85°C for 10–30 seconds followed by compression through a ring die at frictional temperatures of 75–95°C depending on die specification and throughput. Published stability data for purified dianthin saponins indicate measurable aglycone release—consistent with acid-catalyzed glycosidic bond hydrolysis—when aqueous extracts are held at 80°C for periods exceeding 20 minutes at pH 5.5, while exposure at 90°C for 10 minutes produces total saponin recovery below 85% by high-performance liquid chromatography with evaporative light scattering detection, per the analytical methodology detailed in pharmacopeial monographs for triterpenoid saponin quantification. For this reason, direct incorporation of unprotected extract powder into pre-conditioning mash is contraindicated; instead, three processing alternatives are industry-validated. The first involves post-pellet vacuum coating, in which pelleted and cooled feed is transferred to a vacuum infuser operating at −0.6 to −0.8 bar and sprayed with an aqueous extract solution representing 2–5% w/w of pellet weight, allowing absorption of the active phase into pore spaces without exposing the saponins to die friction heat. The second route is cold pelletization at conditioning temperatures held at 40–50°C using a modified conditioner with reduced steam injection, which limits throughput to approximately 60–70% of nominal capacity on standard 10–15 t/h production lines but preserves total saponin recovery above 95%. The third—and most capital-intensive—option is microencapsulation of the extract via fluidized-bed bottom-spray coating with hydrogenated palm oil (melting point 45–50°C) at core-to-coating ratio 1:2 w/w, producing free-flowing microcapsules with D₅₀ of 200–400 μm that withstand direct extrusion temperatures up to 100°C for 45 seconds with less than 8% active loss. The API inclusion rate in finished feed for broiler renal syndrome management—specifically visceral gout, nephritis, and urate deposition associated with high-calcium, low-phosphorus diets—ranges from 0.2% to 1.0% w/w of the 10:1 standardized extract, equivalent to 200–1,000 g of extract per ton of complete feed, with the lower end applied prophylactically during week 2–3 of production and the upper end deployed therapeutically for 5–7 days following clinical diagnosis of renal distress. Homogeneity of the extract in the feed matrix is verified by sampling 10 locations from the final mixer discharge and confirming coefficient of variation below 5% by UV spectrophotometric determination of total saponins at 544 nm following vanillin-sulfuric acid derivatization. Quality assurance under this scenario is governed by FAMI-QS Version 6.0 for specialty feed ingredients, China National Standard GB 13078-2017 for feed hygiene limits (including lead at ≤5 mg/kg, arsenic at ≤2 mg/kg, and total aerobic microbial count at ≤10⁴ CFU/g), and the residue safety framework of VICH GL48 for marker residue depletion in food-producing animals. Finished product types under this scenario include 25 kg multi-wall paper premix bags with polyethylene liner, 5 kg vacuum-sealed premix pouches for integrator feed mills, and complete pelleted feed delivered to commercial broiler houses.

Bovine Oral Drench Formulation: pH, Viscosity, and Sedimentation Kinetics

Suspension stability in ruminant oral drench vehicles is determined by three interrelated parameters that must be simultaneously controlled to prevent nozzle clogging, dose inaccuracy, and sedimentation-driven potency loss during storage of 1 L and 5 L HDPE containers. The pH of the finished drench is maintained between 5.0 and 7.0 using citrate-phosphate buffer; below pH 4.0, measurable hydrolytic cleavage of the rhamnose and fucose glycosidic bonds in dianthin saponins occurs within 72 hours at 40°C, releasing sapogenin aglycones that exhibit reduced diuretic activity in rodent and bovine models. Viscosity is held below 50 mPa·s at 25°C as determined on a Brookfield DVII+ viscometer using spindle 2 at 60 rpm; viscosities above this threshold produce unacceptable flow rates through standard balling-gun and drench-nozzle geometries, with measured delivery rates falling below 80% of the target volume in 10-second administration windows on automated drenching systems. Suspending agents are limited to xanthan gum at 0.15–0.30% w/w or microcrystalline cellulose-sodium carboxymethylcellulose co-processed grades at 0.5–1.0% w/w, both selected for their thixotropic flow behavior that yields low viscosity under shear but sufficient yield stress (0.5–2.0 Pa) to suspend particulate matter at rest. The extract particle size in suspension formulations is reduced by wet milling to D₉₀ < 25 μm as confirmed by laser diffraction on a Malvern Mastersizer 3000, and the sedimentation volume ratio F exceeds 0.8 after 24 hours per Ph. Eur. 2.9.36, indicating acceptable flocculation-controlled settling. Redispersibility of sediment is achieved with fewer than 10 manual inversions of the 1 L container. The active loading is 5–10% w/v of the 10:1 Dianthi Herba extract, equivalent to 50–100 mg/mL total solids, deployed for bovine nephritis, postpartum urinary retention, and edema secondary to mastitis-associated endotoxemia at dosing rates of 1–2 mL per 10 kg body weight administered orally once daily for 3–5 days. Preservative efficacy is validated according to Ph. Eur. 5.1.3 with sodium methylparaben at 0.10% w/w and sodium propylparaben at 0.02% w/w; challenge testing with Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis demonstrates bacterial reduction of at least 3 log₁₀ units within 7 days and no fungal recovery increase at 28 days. Extraction of the herbal material preceding formulation follows a two-cycle aqueous reflux at 85°C for 2 hours per cycle using a 1:10 herb-to-solvent ratio, followed by vacuum concentration at 60–65°C under −0.08 MPa to a relative density of 1.20–1.25 at 25°C; ethanol precipitation at final concentration 60% v/v is then applied to remove high-molecular-weight polysaccharides and proteins that would otherwise increase viscosity beyond the specified limit and accelerate microbial growth. Compliance anchors for this application include the Chinese Veterinary Pharmacopoeia (2020 edition) Vol. I oral solution monograph, VICH GL52 for bioequivalence of oral veterinary formulations, and the pharmacovigilance reporting requirements under EU Regulation 2019/6 Article 73. Terminal finished product forms include ready-to-use oral drench solutions in amber 1 L and 5 L HDPE bottles sealed with induction-foil caps, single-dose 50 mL squeeze containers for calf administration, and bulk 20 L carboys for large-herd automated drenching lines.Tablet compression of Dianthi Herba extract powders presents characteristic flow and compressibility deficiencies attributable to the high residual saponin content, which lowers bulk density to 0.35–0.50 g/cm³ and produces angle of repose values in the range of 38–45° by funnel method, exceeding the 35° threshold generally considered compatible with high-speed rotary press operation. Direct compression is therefore contraindicated for extract loadings above 20% w/w; the preferred manufacturing route for companion animal urinary-tract support tablets is dry granulation via roller compaction, which imparts sufficient particle-size enlargement without exposing the hygroscopic extract to aqueous or organic granulating fluids. Roller compaction is executed on a Gerteis Mini-Pactor with roll pressure maintained at 4–8 MPa, roll speed at 5–15 rpm, gap width at 2.0–3.5 mm, and screen milling of the compacted ribbon through 1.0 mm and 1.6 mm aperture sizes in two-stage configuration; resulting granules exhibit bulk density of 0.55–0.70 g/cm³ and Carr index below 20%, permitting acceptable die-fill consistency at turret speeds up to 60 rpm on a Korsch XL 100 rotary tablet press. The compressed tablet formula contains 30–50% w/w of the 10:1 Dianthi Herba extract (standardized to 12.0–18.0% total saponins and 2.0–4.0% total flavonoids), 40–60% w/w microcrystalline cellulose (Avicel PH-102), 5–10% w/w crospovidone as disintegrant, 0.5–2.0% w/w colloidal silicon dioxide as glidant, and 0.5–1.5% w/w magnesium stearate as lubricant applied in the final 3 minutes of blending. Each tablet contains 100–250 mg of standardized extract, equivalent to 1.0–2.5 g of crude herb per unit dose, with dosing for dogs at 1 tablet per 10 kg body weight twice daily and for cats at ½ tablet per 5 kg body weight once daily for periods of 14–28 days. Physicochemical acceptance criteria include tablet hardness of 60–100 N on the Stokes-Merrill instrument, friability below 1.0% per USP <1216>, and disintegration time below 15 minutes in water at 37°C per USP <701>. Dissolution testing is performed per USP <711> using Apparatus 2 (paddle) at 50 rpm in 900 mL of 0.1 N hydrochloric acid for the first 2 hours followed by pH 6.8 phosphate buffer; Q is not less than 75% of total saponins released at 45 minutes. For capsule manufacturing, the extract powder is blended with dibasic calcium phosphate dihydrate and magnesium stearate at 0.5% w/w, filled into size 0 or size 1 hydroxypropyl methylcellulose capsules on a Bosch GKF 700 machine operating at 60–80% of rated speed, with fill-weight coefficient of variation below 5% and in-process weight checks every 15 minutes. This application is governed by FDA 21 CFR Part 111 when marketed as an animal supplement in the United States, with NASC (National Animal Supplement Council) audit participation as a de facto market-access prerequisite for retail distribution; analytical testing follows USP General Chapters applicable to botanical dietary supplements. Terminal finished product forms include uncoated and film-coated tablets in 60-count, 120-count, and 240-count HDPE bottles with child-resistant closures, blister-packaged tablets in 10-count PVC/PVDC-aluminum strips, and HPMC capsules in 90-count white-polypropylene bottles with desiccant canisters.

When Parenteral Delivery Becomes the Only Viable Route for Acute Urinary Obstruction

Injectable formulations of Dianthi Herba extract represent the most technically constrained application due to the intrinsic hemolytic activity of triterpenoid saponins, pyrogen and endotoxin burdens carried over from the botanical source material, and the thermal instability of dianthin glycosides during terminal sterilization. The hemolytic index—defined as the percentage of erythrocyte lysis induced by a 1 mg/mL solution in physiological saline—must be reduced to below 0.1% for intravenous administration and below 0.5% for intramuscular use, as measured by the erythrocyte hemolysis assay described in the Chinese Veterinary Pharmacopoeia (2020 edition) Appendix 1141. Crude aqueous extracts of Dianthi Herba typically exhibit hemolytic indices in the range of 1.5–5.0%, necessitating a multi-stage purification cascade that begins with ethanol precipitation at 75% v/v to remove high-molecular-weight polysaccharides, followed by macroporous adsorptive resin chromatography on AB-8 or D101 styrene-divinylbenzene resin, wherein saponins are eluted with 70% v/v ethanol while polar impurities are removed in the aqueous flow-through. The purified eluate is concentrated and subjected to tangential-flow ultrafiltration across a 10 kDa molecular-weight cut-off polyethersulfone membrane at transmembrane pressure of 0.2–0.4 MPa and crossflow velocity of 3–5 m/s, producing a retentate with total saponin content of 40–60% w/w that is spray dried or lyophilized for use in the injectable compounding process. Endotoxin content is controlled through the use of depyrogenated processing equipment and sterile water for injection; the acceptance limit is 0.5 EU/mg of extract as determined by Limulus amebocyte lysate kinetic-turbidimetric assay per Ph. Eur. 2.6.14, with typical batch values after purification falling between 0.05 EU/mg and 0.3 EU/mg. The injectable solution is formulated at 0.1–1.0% w/v of purified extract (equivalent to 1–10 mg/mL total saponins) in sterile water for injection adjusted to isotonicity with 0.9% sodium chloride and buffered to pH 6.5–7.5 with tromethamine or disodium hydrogen phosphate; the solution is passed through a 0.22 μm PVDF sterilizing-grade membrane and filled under Grade A laminar airflow within a Grade B cleanroom environment conforming to EU GMP Annex 1 and WHO TRS 986 Annex 6. Two sterilization strategies are validated: aseptic filtration alone, preserving saponin integrity with less than 3% assay loss, and terminal autoclaving at 121°C for 15 minutes, which produces assay losses of 8–15% and is therefore reserved for intramuscular products where the higher post-sterilization active concentration can be compensated by overage. Particulate matter limits follow USP <788> for small-volume parenterals: not more than 6,000 particles ≥10 μm and 600 particles ≥25 μm per container as determined by light-obscuration counting on a Beckman Coulter HIAC instrument. Stability in the final container-closure system is validated at accelerated conditions of 40°C/75% RH for 6 months and long-term at 2–8°C for 24 months; saponin content is monitored by high-performance liquid chromatography with evaporative light scattering detection using a C18 column and gradient elution of acetonitrile-water containing 0.1% formic acid. The injectable route is indicated only for acute urinary obstruction, severe nephritis with anuria, or perioperative diuresis support in dogs, cats, and horses where oral administration is not feasible; the use in food-producing species requires withdrawal periods established per VICH GL48 marker residue depletion protocols. Published data for the specific pharmacokinetic profile of injectable Dianthi Herba in target veterinary species is limited; bioequivalence and tissue distribution studies are required on a case-by-case basis for regulatory submission. Terminal finished product forms include sterile injectable solutions in 10 mL and 20 mL amber Type I glass ampoules, lyophilized powders for reconstitution in 250 mg and 500 mg fill volumes in Type I tubular vials closed with bromobutyl rubber stoppers, and pre-filled syringes for emergency veterinary practice use.

Aquaculture Immersion Protocols and Microencapsulated Feed Delivery for Renal Support

In intensive recirculating aquaculture systems and pond-based freshwater fish production, Dianthi Herba extract is applied through two distinct delivery routes—static immersion baths and microencapsulated feed additives—each governed by different pharmacokinetic considerations and water-stability requirements that diverge fundamentally from terrestrial animal applications. For immersion therapy, the extract is dissolved or dispersed in aerated tank water at a final concentration of 5–10 mg/L, with a minimum exposure duration of 30–60 minutes and repeated application every 24 hours for 3–5 consecutive days; this protocol is applied for supporting renal function during bacterial nephritis outbreaks in cyprinids and for reducing uremic stress during transport of ornamental koi and goldfish. The concentrated immersion product is manufactured as a cold aqueous extract at temperatures not exceeding 60°C (deliberately reduced from the 85°C reflux temperatures used for oral formulations to minimize foaming driven by the surfactant properties of dianthin saponins), in which the saponins themselves act as natural wetting agents that enhance gill-tissue penetration. The extract concentrate for immersion baths is filtered through 5 μm polypropylene depth filters to remove particulate matter that could interfere with oxygen transfer at the air-water interface, and stabilized with 0.1% sodium benzoate to suppress microbial growth during storage at 15–25°C. For feed delivery, the extract powder cannot be applied as a simple surface dusting because of rapid aqueous leaching; microencapsulation by spray chilling is the validated route, using hydrogenated palm stearin (melting point 45–50°C) as the wall material and the extract as the core at core-to-wall ratio 1:3 w/w, producing spherical microcapsules with D₅₀ of 150–350 μm that are incorporated into extruded or cold-pelleted aquafeed at 0.5–2.0% w/w. Water stability of the finished medicated feed is evaluated by the immersion test specified in ISO 13903:2005, with acceptable formulations retaining at least 85% of the microcapsule-associated saponins after 30 minutes of immersion in water at 25°C, while unprotected extract powders lose more than 50% of active content within 5 minutes under identical conditions. Leaching kinetics are quantified by UV spectrophotometric measurement of total saponins in the immersion medium at timed intervals; acceptable products exhibit first-order leaching rate constants below 0.005 min⁻¹ over the first 30 minutes. Manufacturing compliance for aquaculture applications follows ISO 22000:2018 food safety management, HACCP principles per Codex Alimentarius CXC 1-1969, and the regulatory framework of EU Regulation 1831/2003 for feed-additive authorization in aquaculture species; environmental discharge of saponin-containing bath water should be evaluated against local permitted effluent microbial and chemical oxygen demand limits, as saponins are known surfactant stressors to receiving aquatic ecosystems at concentrations above 1 mg/L. Finished product types under this scenario include 1 L and 5 L immersion bath concentrates in amber PET bottles, 10 kg and 25 kg microencapsulated feed-additive bags, and fully compounded sinking medicated feed pellets for freshwater aquaculture species including common carp (Cyprinus carpio), tilapia (Oreochromis niloticus), and channel catfish (Ictalurus punctatus).

Formulation Parameter	Extract:Carrier 1:1 w/w	Extract:Carrier 1:2 w/w	Extract:Carrier 1:3 w/w
Spray dryer outlet temperature (°C)	75–85	72–82	70–80
Particle D₅₀ (μm, Malvern 3000)	35–65	28–52	22–44
Moisture pickup at 75% RH/25°C, 48 h (%)	4.5–6.0	3.2–4.5	2.5–3.5
Dissolution time in 25°C water (min)	2.5–4.0	1.5–3.0	1.0–2.5
Total saponin recovery after 24 months (%)	91–94	94–96	96–98
Angle of repose, loose pour (°)	36–42	33–38	30–35

For the injectable route, batch-to-batch consistency of the hemolytic index is established by triplicate testing across 10 g samples drawn from the top, middle, and bottom of each purification-lot container; the coefficient of variation across a minimum of 5 production lots must not exceed 15%, and any lot exceeding hemolytic index 0.5% at 1 mg/mL is rejected for parenteral use and re-designated for oral product manufacturing. Ultrafiltration membrane integrity is verified before and after each processing campaign by bubble-point testing at 2.8–3.2 bar for the 0.22 μm sterilizing filters and pressure-hold testing for the 10 kDa tangential-flow cassettes, per PDA Technical Report 26. Sterile filtration of the injectable solution is performed at a terminal filter loading of 0.5–1.0 L/m² membrane area, with filter integrity re-tested post-use; any failed integrity test invalidates the entire batch. Depyrogenation of glass ampoules and vials is executed in a validated stainless-steel tunnel at 250°C for not less than 45 minutes (for Type I glass) per Ph. Eur. 5.1.1, producing an endotoxin reduction factor exceeding 3 log₁₀ units. Lyophilization of the injectable powder is performed with a primary drying shelf temperature of −20°C for 24 hours, secondary drying ramp to 25°C, and final chamber vacuum release with sterile-filtered nitrogen; the lyophilized cake must reconstitute to a clear solution in 3 minutes at 25°C with less than 1% insoluble residue.

Quality Attribute	Test Method Designation	Acceptance Limit	Applicable Scenario
Total dianthin saponins	HPLC-ELSD, ChP 2020 Vol. I	12.0–18.0% w/w in extract	All scenarios
Loss on drying	Ph. Eur. 2.2.32	≤ 5.0%	Powders, granules, tablets
Total aerobic microbial count	Ph. Eur. 2.6.12	≤ 10³ CFU/g	Oral dosage forms
Total yeast and mold count	Ph. Eur. 2.6.12	≤ 10² CFU/g	Oral dosage forms
E. coli absence	Ph. Eur. 2.6.13	Absent in 1 g	All scenarios
Endotoxin (injectable)	Ph. Eur. 2.6.14, LAL kinetic	≤ 0.5 EU/mg extract	Parenteral
Hemolytic index	ChP 2020 Appendix 1141	≤ 0.5% at 1 mg/mL	Parenteral
Particulate matter ≥10 μm	USP <788>, Method 1	≤ 6,000/container	Parenteral
Particulate matter ≥25 μm	USP <788>, Method 1	≤ 600/container	Parenteral
Feed homogeneity CV	FAMI-QS 6.0 sampling plan	≤ 5%	Premix, poultry feed
Water stability (aquafeed)	ISO 13903:2005	≥ 85% retention at 30 min	Aquaculture
Dissolution (tablets)	USP <711>, Apparatus 2	≥ 75% at 45 min	Companion animal
Preservative efficacy	Ph. Eur. 5.1.3	≥ 3 log₁₀ reduction, bacteria	Oral drench